Position in KRYS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,261,240
+$1,703,481 QoQ
Shares Held
6,084
-43.0% QoQ
Ownership
0.021%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#155
of 419 holders
Holding Since
Jun 2020
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in KRYS Over Time
Shares Held
Position Value (USD)
Derivatives in KRYS
reported options exposure · as of Jun 30, 2026CallValue
$929,175
CallShares
2,500
PutValue
$483,171
PutShares
1,300
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026TWO SIGMA INVESTMENTS, LP holds $7,273,657,992 across 342 Biotechnology names. KRYS ranks #150 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,875,937 | $564,713,315 | |
| 2 | MRNA |
Moderna, Inc.
|
7,193,530 | $503,762,905 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
6,252,342 | $495,748,197 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
656,124 | $409,119,558 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
4,722,185 | $351,708,338 | |
| 6 | EXEL |
Exelixis, Inc.
|
4,209,861 | $229,058,537 | |
| 7 | INCY |
Incyte Corp
|
2,003,559 | $227,123,448 | |
| 8 | ARGX |
Argenx SE
|
185,638 | $172,229,367 |
All Filings in KRYS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $483,171 | 1,300 | Put | Sole | 2026-08-14 | |
| 2026-06-30 | $929,175 | 2,500 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $2,261,240 | 6,084 | Shares | Sole | 2026-08-14 | |
| 2021-09-30 | $557,759 | 10,683 | Shares | Sole | 2021-11-15 | |
| 2020-06-30 | $275,567 | 6,653 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||